OPEN BMC cancer | 1 Jun 2017
G Johnen, K Gawrych, I Raiko, S Casjens, B Pesch, DG Weber, D Taeger, M Lehnert, J Kollmeier, T Bauer, AW Musk, BWS Robinson, T Brüning and J Creaney
Malignant mesothelioma (MM) is a deadly cancer mainly caused by previous exposure to asbestos. With a latency period up to 50 years the incidence of MM is still increasing, even in countries that banned asbestos. Secondary prevention has been established to provide persons at risk regular health examinations. An earlier detection with tumor markers might improve therapeutic options. Previously, we have developed a new blood-based assay for the protein marker calretinin. Aim of this study was the verification of the assay in an independent study population and comparison with the established marker mesothelin.
* Data courtesy of Altmetric.com